Investors Hope the Dogs of the Dow Can Find Their Bite

[ad_1] The Dogs of the Dow weren’t the best in show last year, but the recent rally in beaten-down corners of the stock market is giving hope to fans of…

Puerto Rico Was Supposed to Be John Paulson’s Paradise. Then Came the Lawsuits.

[ad_1] John Paulson made a fortune on Wall Street betting the housing market would collapse. His reinvention as a property tycoon opening Puerto Rico to the wealthy is proving trickier.…

Never Mind Covid, Investors Want a Pfizer Obesity Pill

[ad_1] Some of this year’s best performers in the healthcare sector are companies expected to profit from the anti-obesity drug craze, with Eli Lilly and Novo Nordisk shares both up…

Amgen Could Get a Piece of the Obesity Market

[ad_1] Amgen has a couple of shots on goal to break into one of the biggest markets the pharmaceutical industry has ever seen. [ad_2] Source link

WSJ News Exclusive | The Hedge Fund That Made a Killing Betting Against Lina Khan

[ad_1] Pentwater Capital predicted that FTC efforts to block big deals would fail. [ad_2] Source link

Big Pharma’s Battle With the Biden Administration Could Have Legs

[ad_1] Wall Street should pay attention as the pharma industry mounts a widening legal campaign against the Inflation Reduction Act. [ad_2] Source link

Biden FTC’s Antitrust Bark Proves Worse Than Its Bite

[ad_1] The FTC settlement with Amgen will pave the way for more healthcare deal making. [ad_2] Source link

Amgen’s $27.8 Billion Deal for Horizon Therapeutics Clears Key Hurdle

[ad_1] The Federal Trade Commission said it had agreed to end its legal challenge of the $27.8 billion deal. The pact also dismisses the antitrust claims of six states that…

3M, Jabil, Hawaiian Electric, Boston Scientific, XPeng, Nvidia, and More Stock Market Movers

[ad_1] 3M (ticker: MMM) rose 5.3% following a report from The Wall Street Journal that said the company and plaintiffs attorneys were nearing a settlement in which 3M would pay…

FTC Pauses Challenge to Amgen’s $27.8 Billion Deal for Horizon Therapeutics

[ad_1] The move gives the agency time to weigh a settlement that would allow the deal to close with conditions. [ad_2] Source link